Patient characteristics and tumor antigen expression
| Ny-ESO-1/ISCOMATRIX (n=56) | Iscomatrix (n=54) | P value | |
| Mean age (years) | 54.5 | 53.0 | 0.261* |
| Sex, n (%) | 0.477† | ||
| Female | 37 (66.1) | 32 (59.3) | |
| Male | 19 (33.9) | 22 (40.7) | |
| Race | 1.00‡ | ||
| White, n (%) | 56 (100) | 54 (100) | |
| Eastern Cooperative Oncology Group (ECOG) performance status, n (%) | 0.044† | ||
| 0 | 51 (91.1) | 44 (81.5) | |
| 1 | 2 (3.6) | 8 (14.8) | |
| 2–4 | 0 (0.0) | 0 (0.0) | |
| American Joint Committee on Cancer (AJCC) stage at study entry, n (%) | 0.617† | ||
| IIC | 2 (3.6) | 7 (13.0) | |
| IIIB | 25 (44.6) | 18 (33.3) | |
| IIIC | 11 (19.6) | 12 (22.2) | |
| IV | 18 (32.1) | 17 (31.5) | |
| Ulceration, n (%) | 0.024† | ||
| No | 27 (48.2) | 17 (31.5) | |
| Unknown | 20 (35.7) | 19 (35.2) | |
| Yes | 9 (16.1) | 18 (33.3) | |
| Tumor antigen expression | 0.114* | ||
| ≤5% | 26 (46.4%) | 28 (51.9%) | |
| 6%–25% | 5 (8.9%) | 10 (18.5%) | |
| 26%–50% | 2 (3.6%) | 3 (5.6%) | |
| 51%–75% | 6 (10.7%) | 4 (7.4%) | |
| >75% | 17 (30.4%) | 9 (16.7%) | |
*From an ANOVA test with factors treatment and location (UK or Australia/New Zealand).
†From a Cochran-Mantel-Haenszel test adjusting for location (UK or Australia/New Zealand).
‡Unable to calculate Cochran-Mantel-Haenszel due to insufficient value variations.
ANOVA, analysis of variance.